Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility

Park S.; Jo K-W; Shim T. S.

首页> 外文期刊>The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease >Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility

【24h】

Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility

机译：根据吡嗪酰胺敏感性的多药抗性结核病治疗结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND: Pyrazinamide (PZA) is an important anti-tuberculosis drug for multidrug-resistant tuberculosis (MDR-TB). However, PZA has recently been demoted within the hierarchy of TB drugs used for MDR-TB.

机译：背景：吡嗪酰胺（PZA）是一种重要的抗结核药物，用于多药抗性结核（MDR-TB）。然而，PZA最近在用于MDR-TB的结核病药物的层次内进行了分布。

著录项

来源
《The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease》 |2020年第2期|共8页
作者
Park S.; Jo K-W; Shim T. S.;
展开▼
作者单位

Gangneung Asan Hosp Dept Pulm Allergy &

Crit Care Med Kangnung South Korea;

Univ Ulsan Asan Med Ctr Dept Pulm &

Crit Care Med Coll Med 88 Olymp Ro 43 Gil Seoul 05505;

Univ Ulsan Asan Med Ctr Dept Pulm &

Crit Care Med Coll Med 88 Olymp Ro 43 Gil Seoul 05505;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词
MDR-TB; PZA; treatment outcome; TB;

机译：MDR-TB;PZA;治疗结果;TB;

相似文献

外文文献
中文文献
专利

1. FG020326通过增加泰素帝介导caspase-8和3激活的敏感性克服多药耐药细胞MCF-7/ADR的凋亡抗性 [J] . 王秀文, 丁岩, 梁永钜, 癌症（英文版） . 2004,第0z1期
2. Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility [J] . Park S., Jo K-W, Shim T. S. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease . 2020,第2期

机译：根据吡嗪酰胺敏感性的多药抗性结核病治疗结果
3. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs [J] . Marlanka AZuur, Jotam GPasipanodya, Dickvan Soolingen, Clinical infectious diseases . 2018,第11期

机译：中间敏感性剂量依赖性断裂点，用于高剂量利福平，异烟肼和吡唑胺治疗在多药抗性结核计划中
4. Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment" [J] . Fofana M. O., Dowdy D. W. Antimicrobial agents and chemotherapy. . 2017,第6期

机译：回复安东尼等人，“保护吡嗪酰胺，优先改善多药抗性结核病治疗中的结果”
5. Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility [C] . Chakshu Vats, Jaspreet Kaur Dhanjal, Sukriti Goyal, Asia-Pacific Bioinformatics Conference . 2015

机译：机械分析阐明了结核分枝杆菌吡嗪酰胺酶和吡嗪酰胺敏感性术中Lys96突变的关系
6. Correlates of treatment outcomes of Multidrug-Resistant Tuberculosis (MDR-TB): a systematic review and meta-analysis. [D] . Akcakir, Yasemin. 2009

机译：耐多药结核病（MDR-TB）治疗结果的相关性：系统评价和荟萃分析。
7. Reply to Anthony et al. Protecting Pyrazinamide a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment [O] . M. O. Fofana, D. W. Dowdy 2017

机译：答复安东尼等人保护吡嗪酰胺这是改善耐多药结核病治疗结果的优先事项
8. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs [O] . Marlanka A Zuur, Jotam G Pasipanodya, Dick van Soolingen, 2018

机译：高剂量利福平，异烟肼和吡唑胺治疗在多药抗性结核计划中的中间敏感性依赖性断裂点

Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility

摘要

著录项

相似文献

相关主题

期刊订阅